English
简体中文
Total: £ 56.28
Published Date: 2025-11-05 | Pages: 132 | Tables: 148 | Pharma & Healthcare
The global Women Sexual Disorder Drugs Treating market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Several drugs are utilized in treating various sexual disorders in women. For instance, hypoactive sexual desire disorder (HSDD) can be addressed with medications like flibanserin (Addyi) or bremelanotide (Vyleesi), which work to increase sexual desire.
From a downstream perspective, Hospital Pharmacies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Women Sexual Disorder Drugs Treating leading manufacturers including Pfizer, Teva Pharmaceuticals, Duchesnay, Sprout Pharmaceuticals, Cosette Pharmaceuticals, Lupin, etc., dominate supply; the top five capture approximately % of global revenue, with Pfizer leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Women Sexual Disorder Drugs Treating market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Pfizer
Teva Pharmaceuticals
Duchesnay
Sprout Pharmaceuticals
Cosette Pharmaceuticals
Lupin
Segment by Type
Estrogen Therapy
Ospemifene
Flibanserin
Bremelanotide
Others
Segment by Application
Hospital Pharmacies
Private Clinics
Retail Pharmacies
E-Commerce (B2B)
E-Commerce (B2C)
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Women Sexual Disorder Drugs Treating study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Women Sexual Disorder Drugs Treating: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Women Sexual Disorder Drugs Treating Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Estrogen Therapy
1.2.3 Ospemifene
1.2.4 Flibanserin
1.2.5 Bremelanotide
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Women Sexual Disorder Drugs Treating Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Private Clinics
1.3.4 Retail Pharmacies
1.3.5 E-Commerce (B2B)
1.3.6 E-Commerce (B2C)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Women Sexual Disorder Drugs Treating Revenue Estimates and Forecasts 2020-2031
2.2 Global Women Sexual Disorder Drugs Treating Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Women Sexual Disorder Drugs Treating Sales Estimates and Forecasts 2020-2031
2.4 Global Women Sexual Disorder Drugs Treating Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Women Sexual Disorder Drugs Treating Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Women Sexual Disorder Drugs Treating Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Estrogen Therapy Market Size by Manufacturers
3.5.2 Ospemifene Market Size by Manufacturers
3.5.3 Flibanserin Market Size by Manufacturers
3.5.4 Bremelanotide Market Size by Manufacturers
3.5.5 Others Market Size by Manufacturers
3.6 Global Women Sexual Disorder Drugs Treating Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Women Sexual Disorder Drugs Treating Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Women Sexual Disorder Drugs Treating Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Women Sexual Disorder Drugs Treating Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Women Sexual Disorder Drugs Treating Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Women Sexual Disorder Drugs Treating Sales and Revenue by Type (2020-2031)
6.4 North America Women Sexual Disorder Drugs Treating Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Women Sexual Disorder Drugs Treating Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Women Sexual Disorder Drugs Treating Sales and Revenue by Type (2020-2031)
7.4 Europe Women Sexual Disorder Drugs Treating Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Women Sexual Disorder Drugs Treating Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Women Sexual Disorder Drugs Treating Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Women Sexual Disorder Drugs Treating Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Women Sexual Disorder Drugs Treating Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Women Sexual Disorder Drugs Treating Sales and Revenue by Type (2020-2031)
9.4 Central and South America Women Sexual Disorder Drugs Treating Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Women Sexual Disorder Drugs Treating Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Women Sexual Disorder Drugs Treating Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Women Sexual Disorder Drugs Treating Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Women Sexual Disorder Drugs Treating Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Women Sexual Disorder Drugs Treating Product Models, Descriptions and Specifications
11.1.4 Pfizer Women Sexual Disorder Drugs Treating Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Pfizer Women Sexual Disorder Drugs Treating Sales by Product in 2024
11.1.6 Pfizer Women Sexual Disorder Drugs Treating Sales by Application in 2024
11.1.7 Pfizer Women Sexual Disorder Drugs Treating Sales by Geographic Area in 2024
11.1.8 Pfizer Women Sexual Disorder Drugs Treating SWOT Analysis
11.1.9 Pfizer Recent Developments
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Corporation Information
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Women Sexual Disorder Drugs Treating Product Models, Descriptions and Specifications
11.2.4 Teva Pharmaceuticals Women Sexual Disorder Drugs Treating Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Teva Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Product in 2024
11.2.6 Teva Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Application in 2024
11.2.7 Teva Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Geographic Area in 2024
11.2.8 Teva Pharmaceuticals Women Sexual Disorder Drugs Treating SWOT Analysis
11.2.9 Teva Pharmaceuticals Recent Developments
11.3 Duchesnay
11.3.1 Duchesnay Corporation Information
11.3.2 Duchesnay Business Overview
11.3.3 Duchesnay Women Sexual Disorder Drugs Treating Product Models, Descriptions and Specifications
11.3.4 Duchesnay Women Sexual Disorder Drugs Treating Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Duchesnay Women Sexual Disorder Drugs Treating Sales by Product in 2024
11.3.6 Duchesnay Women Sexual Disorder Drugs Treating Sales by Application in 2024
11.3.7 Duchesnay Women Sexual Disorder Drugs Treating Sales by Geographic Area in 2024
11.3.8 Duchesnay Women Sexual Disorder Drugs Treating SWOT Analysis
11.3.9 Duchesnay Recent Developments
11.4 Sprout Pharmaceuticals
11.4.1 Sprout Pharmaceuticals Corporation Information
11.4.2 Sprout Pharmaceuticals Business Overview
11.4.3 Sprout Pharmaceuticals Women Sexual Disorder Drugs Treating Product Models, Descriptions and Specifications
11.4.4 Sprout Pharmaceuticals Women Sexual Disorder Drugs Treating Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Sprout Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Product in 2024
11.4.6 Sprout Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Application in 2024
11.4.7 Sprout Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Geographic Area in 2024
11.4.8 Sprout Pharmaceuticals Women Sexual Disorder Drugs Treating SWOT Analysis
11.4.9 Sprout Pharmaceuticals Recent Developments
11.5 Cosette Pharmaceuticals
11.5.1 Cosette Pharmaceuticals Corporation Information
11.5.2 Cosette Pharmaceuticals Business Overview
11.5.3 Cosette Pharmaceuticals Women Sexual Disorder Drugs Treating Product Models, Descriptions and Specifications
11.5.4 Cosette Pharmaceuticals Women Sexual Disorder Drugs Treating Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Cosette Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Product in 2024
11.5.6 Cosette Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Application in 2024
11.5.7 Cosette Pharmaceuticals Women Sexual Disorder Drugs Treating Sales by Geographic Area in 2024
11.5.8 Cosette Pharmaceuticals Women Sexual Disorder Drugs Treating SWOT Analysis
11.5.9 Cosette Pharmaceuticals Recent Developments
11.6 Lupin
11.6.1 Lupin Corporation Information
11.6.2 Lupin Business Overview
11.6.3 Lupin Women Sexual Disorder Drugs Treating Product Models, Descriptions and Specifications
11.6.4 Lupin Women Sexual Disorder Drugs Treating Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Lupin Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Women Sexual Disorder Drugs Treating Industry Chain
12.2 Women Sexual Disorder Drugs Treating Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Women Sexual Disorder Drugs Treating Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Women Sexual Disorder Drugs Treating Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Women Sexual Disorder Drugs Treating Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Women Sexual Disorder Drugs Treating Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Women Sexual Disorder Drugs Treating Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Women Sexual Disorder Drugs Treating Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Women Sexual Disorder Drugs Treating Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Women Sexual Disorder Drugs Treating Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Women Sexual Disorder Drugs Treating Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Women Sexual Disorder Drugs Treating Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Women Sexual Disorder Drugs Treating Sales by Region (2020-2025) & (K Units)
Table 8. Global Women Sexual Disorder Drugs Treating Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Women Sexual Disorder Drugs Treating Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Women Sexual Disorder Drugs Treating Sales Share by Manufacturers (2020-2025)
Table 12. Global Women Sexual Disorder Drugs Treating Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Women Sexual Disorder Drugs Treating Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Women Sexual Disorder Drugs Treating by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Women Sexual Disorder Drugs Treating as of 2024)
Table 16. Global Women Sexual Disorder Drugs Treating Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Women Sexual Disorder Drugs Treating Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Women Sexual Disorder Drugs Treating Manufacturing Base and Headquarters
Table 19. Global Women Sexual Disorder Drugs Treating Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Women Sexual Disorder Drugs Treating Sales by Type (2020-2025) & (K Units)
Table 23. Global Women Sexual Disorder Drugs Treating Sales by Type (2026-2031) & (K Units)
Table 24. Global Women Sexual Disorder Drugs Treating Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Women Sexual Disorder Drugs Treating Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Women Sexual Disorder Drugs Treating ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Women Sexual Disorder Drugs Treating Sales by Application (2020-2025) & (K Units)
Table 29. Global Women Sexual Disorder Drugs Treating Sales by Application (2026-2031) & (K Units)
Table 30. Women Sexual Disorder Drugs Treating High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Women Sexual Disorder Drugs Treating Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Women Sexual Disorder Drugs Treating Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Women Sexual Disorder Drugs Treating ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Women Sexual Disorder Drugs Treating Growth Accelerators and Market Barriers
Table 37. North America Women Sexual Disorder Drugs Treating Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Women Sexual Disorder Drugs Treating Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Women Sexual Disorder Drugs Treating Growth Accelerators and Market Barriers
Table 40. Europe Women Sexual Disorder Drugs Treating Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Women Sexual Disorder Drugs Treating Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Women Sexual Disorder Drugs Treating Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Women Sexual Disorder Drugs Treating Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Women Sexual Disorder Drugs Treating Growth Accelerators and Market Barriers
Table 45. Southeast Asia Women Sexual Disorder Drugs Treating Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Women Sexual Disorder Drugs Treating Investment Opportunities and Key Challenges
Table 47. Central and South America Women Sexual Disorder Drugs Treating Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Women Sexual Disorder Drugs Treating Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Women Sexual Disorder Drugs Treating Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Pfizer Corporation Information
Table 51. Pfizer Description and Major Businesses
Table 52. Pfizer Product Models, Descriptions and Specifications
Table 53. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Pfizer Sales Value Proportion by Product in 2024
Table 55. Pfizer Sales Value Proportion by Application in 2024
Table 56. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 57. Pfizer Women Sexual Disorder Drugs Treating SWOT Analysis
Table 58. Pfizer Recent Developments
Table 59. Teva Pharmaceuticals Corporation Information
Table 60. Teva Pharmaceuticals Description and Major Businesses
Table 61. Teva Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Teva Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Teva Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Teva Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Teva Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Teva Pharmaceuticals Women Sexual Disorder Drugs Treating SWOT Analysis
Table 67. Teva Pharmaceuticals Recent Developments
Table 68. Duchesnay Corporation Information
Table 69. Duchesnay Description and Major Businesses
Table 70. Duchesnay Product Models, Descriptions and Specifications
Table 71. Duchesnay Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Duchesnay Sales Value Proportion by Product in 2024
Table 73. Duchesnay Sales Value Proportion by Application in 2024
Table 74. Duchesnay Sales Value Proportion by Geographic Area in 2024
Table 75. Duchesnay Women Sexual Disorder Drugs Treating SWOT Analysis
Table 76. Duchesnay Recent Developments
Table 77. Sprout Pharmaceuticals Corporation Information
Table 78. Sprout Pharmaceuticals Description and Major Businesses
Table 79. Sprout Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Sprout Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Sprout Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Sprout Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Sprout Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Sprout Pharmaceuticals Women Sexual Disorder Drugs Treating SWOT Analysis
Table 85. Sprout Pharmaceuticals Recent Developments
Table 86. Cosette Pharmaceuticals Corporation Information
Table 87. Cosette Pharmaceuticals Description and Major Businesses
Table 88. Cosette Pharmaceuticals Product Models, Descriptions and Specifications
Table 89. Cosette Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Cosette Pharmaceuticals Sales Value Proportion by Product in 2024
Table 91. Cosette Pharmaceuticals Sales Value Proportion by Application in 2024
Table 92. Cosette Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 93. Cosette Pharmaceuticals Women Sexual Disorder Drugs Treating SWOT Analysis
Table 94. Cosette Pharmaceuticals Recent Developments
Table 95. Lupin Corporation Information
Table 96. Lupin Description and Major Businesses
Table 97. Lupin Product Models, Descriptions and Specifications
Table 98. Lupin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Lupin Recent Developments
Table 100. Key Raw Materials Distribution
Table 101. Raw Materials Key Suppliers
Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 103. Milestones in Production Technology Evolution
Table 104. Distributors List
Table 105. Market Trends and Market Evolution
Table 106. Market Drivers and Opportunities
Table 107. Market Challenges, Risks, and Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Women Sexual Disorder Drugs Treating Product Picture
Figure 2. Global Women Sexual Disorder Drugs Treating Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Estrogen Therapy Product Picture
Figure 4. Ospemifene Product Picture
Figure 5. Flibanserin Product Picture
Figure 6. Bremelanotide Product Picture
Figure 7. Others Product Picture
Figure 8. Global Women Sexual Disorder Drugs Treating Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital Pharmacies
Figure 10. Private Clinics
Figure 11. Retail Pharmacies
Figure 12. E-Commerce (B2B)
Figure 13. E-Commerce (B2C)
Figure 14. Women Sexual Disorder Drugs Treating Report Years Considered
Figure 15. Global Women Sexual Disorder Drugs Treating Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 17. Global Women Sexual Disorder Drugs Treating Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 18. Global Women Sexual Disorder Drugs Treating Revenue Market Share by Region (2020-2031)
Figure 19. Global Women Sexual Disorder Drugs Treating Sales (2020-2031) & (K Units)
Figure 20. Global Women Sexual Disorder Drugs Treating Sales (CAGR) by Region (2020-2031) (K Units)
Figure 21. Global Women Sexual Disorder Drugs Treating Sales Market Share by Region (2020-2031)
Figure 22. Top 5 and Top 10 Manufacturers Women Sexual Disorder Drugs Treating Sales Volume Market Share in 2024
Figure 23. Global Women Sexual Disorder Drugs Treating Revenue Market Share Ranking (2024)
Figure 24. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 25. Estrogen Therapy Revenue Market Share by Manufacturer in 2024
Figure 26. Ospemifene Revenue Market Share by Manufacturer in 2024
Figure 27. Flibanserin Revenue Market Share by Manufacturer in 2024
Figure 28. Bremelanotide Revenue Market Share by Manufacturer in 2024
Figure 29. Others Revenue Market Share by Manufacturer in 2024
Figure 30. Global Women Sexual Disorder Drugs Treating Sales Market Share by Type (2020-2031)
Figure 31. Global Women Sexual Disorder Drugs Treating Revenue Market Share by Type (2020-2031)
Figure 32. Global Women Sexual Disorder Drugs Treating Sales Market Share by Application (2020-2031)
Figure 33. Global Women Sexual Disorder Drugs Treating Revenue Market Share by Application (2020-2031)
Figure 34. North America Women Sexual Disorder Drugs Treating Sales YoY (2020-2031) & (K Units)
Figure 35. North America Women Sexual Disorder Drugs Treating Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) in 2024
Figure 37. North America Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Women Sexual Disorder Drugs Treating Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Women Sexual Disorder Drugs Treating Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) in 2024
Figure 47. Europe Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 52. France Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Women Sexual Disorder Drugs Treating Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Women Sexual Disorder Drugs Treating Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 67. India Women Sexual Disorder Drugs Treating Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Women Sexual Disorder Drugs Treating Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Women Sexual Disorder Drugs Treating Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Women Sexual Disorder Drugs Treating Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Women Sexual Disorder Drugs Treating Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Women Sexual Disorder Drugs Treating Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Women Sexual Disorder Drugs Treating Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Women Sexual Disorder Drugs Treating Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Women Sexual Disorder Drugs Treating Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Women Sexual Disorder Drugs Treating Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Women Sexual Disorder Drugs Treating Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Women Sexual Disorder Drugs Treating Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Women Sexual Disorder Drugs Treating Revenue (2020-2025) & (US$ Million)
Figure 88. Women Sexual Disorder Drugs Treating Industry Chain Mapping
Figure 89. Regional Women Sexual Disorder Drugs Treating Manufacturing Base Distribution (%)
Figure 90. Global Women Sexual Disorder Drugs Treating Production Market Share by Region (2020-2031)
Figure 91. Women Sexual Disorder Drugs Treating Production Process
Figure 92. Regional Women Sexual Disorder Drugs Treating Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
